Rituximab Structure
Rituximab ri tux i mab is a human mouse chimeric monoclonal immunoglobulin g1 antibody to the cell surface antigen cd20 also known as human b lymphocyte restricted differentiation antigen.
Rituximab structure. Patent for the drug was issued in 1998 and expired in 2015. Get emergency medical help if you have signs of an allergic reaction hives difficult breathing swelling in your face or throat or a severe skin reaction fever sore throat burning eyes skin pain red or purple skin rash with blistering and peeling. Users can perform simple and advanced searches based on annotations relating to sequence structure and function. The antibody is an igg1 kappa immunoglobulin containing murine light and heavy chain variable region sequences and human constant region sequences 6 label.
To understand the molecular mechanism of recognition of human cd20 by rituximab we determined the crystal structure of the rituximab fab in complex with a synthesized peptide comprising the cd20 epitope residues 163 187 at 26 a resolution. Dosage can vary depending on the desired treatment. Rituximab is a widely used monoclonal antibody drug for treating certain lymphomas and autoimmune diseases. These molecules are visualized downloaded and analyzed by users who range from students to specialized scientists.
Patients with cancer who take rituximab intravenous may be at a greater risk of getting a severe health problem called tumor lysis syndrome tlsthis may lead to death. It is used in the treatment and care of patients with non hodgkins lymphoma chronic lymphocytic leukemia rheumatoid arthritis granulomatosis with polyangiitis and microscopic polyangiitis. Rituximab is a liquid drug that is administered into patients veins. If you used rituximab intravenous when you were pregnant tell your babys doctor.
Some side effects may occur during the injection or within 24 hours afterward. Bp35 which is found on mature b cells as well as 90 of b cell neoplasms such as non hodgkin lymphoma and chronic lymphocytic leukemia. Rituximab was developed by researcher nabil hanna and coworkers at idec pharmaceuticals under the name idec c2b8. Rituximab binds to amino acids 170 173 and 182 185 on cd20 which are physically close to each other as a result of a disulfide bond between amino acids 167 and 183.
As a member of the wwpdb the rcsb pdb curates and annotates pdb data according to agreed upon standards. The rcsb pdb also provides a variety of tools and resources.